A prominent example is the emergence of EGFR T790M “gatekeeper” mutations in tumors at the time of disease recurrence and following initial response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.